SGMO - サンガモ・セラピュ―ティクス （Sangamo Therapeutics Inc.） サンガモ・セラピュ―ティクスSGMOのチャート
SGMOの企業情報
| symbol | SGMO |
|---|---|
| 会社名 | Sangamo Therapeutics Inc （サンガモ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サンガモ・セラピューティクス(Sangamo Therapeutics Inc)（旧名:Sangamo BioSciences Inc）は臨床病期のバイオ技術会社である。同社は化学を、ゲノム編集、遺伝子治療、遺伝子調節及び細胞治療にある同社のプラットフォーム技術を利用することによって患者の生活を変化させるゲノム療法への転換に従事する。同社は臨床開発・臨床前プログラムを開発していて、臨床開発・商業開発を促進するために、バイオ医薬品会社との特定のプログラムを提携させた。同社はヒトの治療法の開発を主とする。同社の製品ラインは、SB-525、SB-FIX、SB-318、SB-913、SB-728-TおよびSB-728-HSPCを含む。同社は血友病Bの治療のためのジンクフィンガーヌクレアーゼ（ZFN）インビボゲノム編集手法を評価する第I / II相臨床試験を開始した。ZFP技術プラットフォームの開発では、ヒト治療・非治療用途のための製品開発にそのリソースを集中している。 サンガモ・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。亜鉛フィンガ―デオキシリボ核酸(DNA)結合タンパク質(ZFP)などの自然発生タンパク質の研究により、遺伝子治療薬の開発・製品化に従事。後天性免疫不全症候群(エイズ)、血友病、ハンチントン病などの遺伝子治療薬を臨床・開発する。本社所在地はカリフォルニア州リッチモンド。 Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering. |
| 本社所在地 | 501 Canal Boulevard Richmond CA 94804 USA |
| 代表者氏名 | Alexander D. Macrae Alexander D. Macrae |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 510-970-6000 |
| 設立年月日 | 34851 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | 182人 |
| url | https://www.sangamo.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/sgmo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -64.84900 |
| 終値（lastsale） | 14.23 |
| 時価総額（marketcap） | 1446817562.11 |
| 時価総額 | 時価総額（百万ドル） 1412.249 |
| 売上高 | 売上高（百万ドル） 58.94200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 898.98300 |
| 当期純利益 | 当期純利益（百万ドル） -62.27200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Sangamo Therapeutics Inc revenues increased from $11.7M to $34.1M. Net loss increased 26% to $36.8M. Revenues reflect Collaboration agreements increase from $11.3M to $33.8M. Higher net loss reflects Other Research and development increase of 92% to $48.9M (expense) Other General and administrative increase of 70% to $18.7M (expense). |
SGMOのテクニカル分析
SGMOのニュース
Sangamo Therapeutics, Inc.: Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 2023/05/02 20:36:00 Finanz Nachrichten
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at …
Sangamo Therapeutics''s Return On Capital Employed Overview 2023/05/01 14:46:30 Benzinga
According to Benzinga Pro data, during Q4, Sangamo Therapeutics (NASDAQ: SGMO ) posted sales of $27.23 million. Earnings were up 2.22%, but Sangamo Therapeutics still reported an overall loss of $51.97 million. In Q3, Sangamo Therapeutics brought in $26.46 million in sales but lost $53.16 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com
H.C. Wainwright maintains Sangamo Therapeutics at Buy with a price target of $5.00 2023/05/01 12:46:57 Investing.com
https://www.investing.com/news/pro/sangamo-bioscienc-receives-investment-bank-analyst-rating-update-3069038
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Lowered by Bank of America 2023/04/30 07:54:45 The AM Reporter
Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) was downgraded by investment analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research note issued on Friday, The Fly reports. They currently have a $1.50 target price on the biopharmaceutical company’s stock, down from their previous target price of $5.00. Bank of […]
Sangamo downgraded to underperform at BofA on restructuring 2023/04/28 14:07:46 Seeking Alpha
BofA Securities has downgraded Sangamo Therapeutics (SGMO) to underperform as the company is undergoing a restructuring to address cash concerns. Read more here.
Sangamo Therapeutics Inc. (SGMO) did well last session? 2023/01/05 12:16:00 US Post News
As of Wednesday, Sangamo Therapeutics Inc.’s (NASDAQ:SGMO) stock closed at $3.33, up from $3.14 the previous day. While Sangamo Therapeutics Inc. has overperformed by 5.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SGMO fell by -57.48%, with highs and lows ranging from $7.99 to $2.72, […]
There Are Mixed Signals on the Chart for Sangamo Therapeutics Inc. (SGMO) 2022/12/29 17:32:00 US Post News
Sangamo Therapeutics Inc. (SGMO)’s stock is trading at $3.04 at the moment marking a rise of 9.35% from the last session close. As of this writing, shares are priced at -62.84% less than their 52-week high of $8.18, and 11.72% over their 52-week low of $2.72. Based on the past 30-day period, the stock price […]
SGMO Stock: More Upside For Sangamo Therapeutics Inc. (NASDAQ: SGMO)? 2022/12/21 12:00:00 Marketing Sentinel
In the last trading session, 1.61 million Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.13. With the company’s per share price at $3.10 changed hands at $0.01 or 0.32% during last session, the market valuation stood at $487.35M. SGMO’s last price was a discount, traded about -179.03% off its 52-week … SGMO Stock: More Upside For Sangamo Therapeutics Inc. (NASDAQ: SGMO)? Read More »
GPRO, SGMO and CALA are among after hour mover 2022/12/16 22:58:39 Seeking Alpha
Gainers: Sanofi (SNY) +6%. Atlis Motor Vehicles (AMV) +5%
Sangamo Therapeutics Inc. (SGMO) is an excellent investment, but the stock is overvalued/undervalued right now 2022/12/16 13:40:00 US Post News
In Thursday’s session, Sangamo Therapeutics Inc. (NASDAQ:SGMO) marked $3.30 per share, down from $3.45 in the previous session. While Sangamo Therapeutics Inc. has underperformed by -4.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SGMO fell by -57.42%, with highs and lows ranging from $8.65 to […]
Looking For A Good Stock? Let This Sangamo Therapeutics Inc. (NASDAQ: SGMO) Analysis Help. 2022/09/28 14:00:00 Stocks Register
Sangamo Therapeutics Inc. (NASDAQ:SGMO) price closed higher on Tuesday, September 27, jumping 4.81% above its previous close. A look at the daily price movement shows that the last close reads $4.78, with intraday deals fluctuated between $4.84 and $5.05. The company’s 5Y monthly beta was ticking 1.44. Taking into account the 52-week price action we … Looking For A Good Stock? Let This Sangamo Therapeutics Inc. (NASDAQ: SGMO) Analysis Help. Read More »
Sangamo Therapeutics Inc. (NASDAQ: SGMO) Is Rated A Buy By Analysts. 2022/09/27 14:00:00 Marketing Sentinel
In the last trading session, 1.05 million Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.30. With the company’s per share price at $4.78 changed hands at -$0.17 or -3.43% during last session, the market valuation stood at $761.88M. SGMO’s last price was a discount, traded about -140.38% off its 52-week … Sangamo Therapeutics Inc. (NASDAQ: SGMO) Is Rated A Buy By Analysts. Read More »
Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy 2022/09/22 21:38:46 Seeking Alpha
A phase 3 trial of Pfizer (PFE) and Sangamo Therapeutics (SGMO) Therapeutics'' giroctocogene fitelparvovec, a gene therapy for hemophilia A, has reopened recruitment.Dosing is expected…
It would be worthwhile to take a closer look at Sangamo Therapeutics Inc. (SGMO) 2022/09/21 12:48:00 US Post News
As of Tuesday, Sangamo Therapeutics Inc.’s (NASDAQ:SGMO) stock closed at $5.30, down from $5.31 the previous day. While Sangamo Therapeutics Inc. has underperformed by -0.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SGMO fell by -42.89%, with highs and lows ranging from $11.49 to $3.12, […]
Weak Fundamental Momentum Sinks Sangamo Therapeutics Inc. 2022/09/20 12:00:00 Marketing Sentinel
Sangamo Therapeutics Inc. (NASDAQ:SGMO) has a beta value of 1.29 and has seen 1.76 million shares traded in the last trading session. The company, currently valued at $918.36M, closed the last trade at $5.31 per share which meant it gained $0.06 on the day or 1.14% during that session. The SGMO stock price is -116.38% … Weak Fundamental Momentum Sinks Sangamo Therapeutics Inc. Read More »